Vicbio Biotechnology Co., Ltd.

+86-19501900054
support@vicbio.com
Imanis Life Sciences

Request Full CatalogsImanis Life Sciences is a biotechnology company focused on regenerative medicine, gene therapy, oncology, and oncolytic virotherapy research. The company provides two core research solution areas: products for oncolytic virus therapy studies and non-invasive imaging reagents for both in vitro and in vivo applications. Its portfolio is centered on high-quality reporter cell lines, lentiviral vectors and gene constructs, NIS- and VSV-specific antibodies, and a comprehensive collection of oncolytic virus resources, supporting translational and preclinical research in cancer biology and therapeutic development.


■ Product Portfolio

Vicbio Biotechnology Co., Ltd. provides the full range of Imanis Life Sciences products.

⇨ Inquire or Order immediately ⇦

Imanis Life Sciences

1. Reporter Lentiviral Vectors and Plasmid Systems

Imanis Life Sciences offers a full range of reporter lentiviral vectors and supporting plasmid systems. Ready-to-use viral particles provide a safe and efficient solution for reporter gene delivery, especially for primary cells and other hard-to-transfect cell types. The company also supplies complete packaging plasmid systems for users who wish to produce lentiviral particles in-house.


2.Stable Cell Lines

The stable cell line portfolio is designed to support both in vitro and in vivo studies in oncology and immuno-oncology. Constitutive reporter cell lines expressing luciferase, fluorescent proteins, or NIS are suitable for applications such as in vitro drug screening and longitudinal tumor monitoring in live animal models. In addition, engineered tumor antigen cell lines with controlled expression of common cancer-associated antigens and therapeutic targets, including CD19, EGFR, and Her2, are available for target validation and therapy-related studies.


3. Oncolytic Virus Resources

Imanis Life Sciences provides a comprehensive oncolytic virus resource portfolio, including ready-to-use viral stocks for in vitro and in vivo research. These products are designed to support the development and evaluation of oncolytic virotherapy approaches across a range of experimental settings.


4. Antibodies

The company offers high-quality NIS antibodies compatible with Western blot, immunohistochemistry, immunofluorescence, and flow cytometry. It also provides multifunctional anti-VSV antibodies suitable for WB, IHC, IF, ELISA, flow cytometry, and VSV neutralization assays, supporting broad applications in virology and imaging-related research.


■ Product List

Product NameCat#SpeciesCell Type
RPMI-8226-Fluc-EmGFPCL177HumanMultiple Myeloma
RPMI-8226-Fluc-PuroCL174HumanMultiple Myeloma
U266B1-Fluc-PuroCL173HumanMultiple Myeloma
U266B1-Fluc-Puro/eGFP-NeoCL176HumanMultiple Myeloma
Raji-Fluc-Puro/CD19-KOCL181HumanB lymphoblast
Raji-Fluc-eGFPCL159HumanB lymphoblast
Raji-Fluc-PuroCL161HumanB Lymphocyte
Daudi-Fluc-eGFPCL158HumanB Lymphoblast
Daudi-Fluc-PuroCL160HumanB Lymphoblast
K562-Fluc-Puro/HuBCMA-NeoCL192HumanChronic Myelogenous Leukemia
K562-Fluc-Puro/HuCD20-NeoCL191HumanChronic Myelogenous Leukemia
K562-Fluc-Puro/HuCD19-PuroCL190HumanChronic Myelogenous Leukemia
K562-Fluc-EmGFPCL169HumanChronic Myelogenous Leukemia
K562-eGFP-PuroCL170HumanChronic Myelogenous Leukemia
K562-Fluc-PuroCL171HumanChronic Myelogenous Leukemia
Nalm6-Fluc-Puro/HuCD19-Puro (mid)CL183HumanChronic Myelogenous Leukemia
Nalm6-Fluc-Puro/HuCD19-Puro (low)CL182HumanChronic Myelogenous Leukemia
Nalm6-Fluc-Puro/CD19-KOCL180HumanPre-B Accute Lymphoblastic Leukemia
Nalm6-Fluc-hNISCL143HumanLymphoma
Nalm6-Fluc-Neo/eGFP-PuroCL150HumanLymphoma
Nalm6-Fluc-PuroCL151HumanLymphoma
Nalm6-eGFP-PuroCL138HumanLymphoma
A549-eGFP-PuroCL079HumanLung Carcinoma
A549-Fluc-PuroCL080HumanLung Carcinoma
A549-hNIS-NeoCL004HumanLung Carcinoma
A549-iRFP-NeoCL081HumanLung Carcinoma
A549-iRFP-PuroCL082HumanLung Carcinoma
A549-Fluc-Neo/eGFP-PuroCL097HumanLung Carcinoma
A549-Fluc-Neo/iRFP-PuroCL098HumanLung Carcinoma
A549-hNIS-Neo/eGFP-PuroCL026HumanLung Carcinoma
A549-hNIS-Neo/Fluc-PuroCL083HumanLung Carcinoma
A549-hNIS-Neo/iRFP-PuroCL084HumanLung Carcinoma
HT1080-EGFR-KOCL175HumanFibrosarcoma
HT1080-eGFP-PuroCL075HumanFibrosarcoma
HT1080-Fluc-PuroCL076HumanFibrosarcoma
HT1080-hNIS-PuroCL102HumanFibrosarcoma
HT1080-iRFP-PuroCL077HumanFibrosarcoma
HT1080-Fluc-Neo/eGFP-PuroCL104HumanFibrosarcoma
HT1080-Fluc-Neo/iRFP-PuroCL106HumanFibrosarcoma
HT1080-hNIS-Neo/eGFP-PuroCL103HumanFibrosarcoma
HT1080-hNIS-Neo/Fluc-PuroCL105HumanFibrosarcoma
HT1080-hNIS-Neo/iRFP-PuroCL107HumanFibrosarcoma
HCT116-eGFP-PuroCL063HumanColorectal Carcinoma
HCT116-Fluc-PuroCL008HumanColorectal Carcinoma
HCT116-hNIS-NeoCL005HumanColorectal Carcinoma
HCT116-iRFP-PuroCL074HumanColorectal Carcinoma
HCT116-Fluc-Neo/eGFP-PuroCL070HumanColorectal Carcinoma
HCT116-Fluc-Neo/iRFP-PuroCL096HumanColorectal Carcinoma
HCT116-hNIS-Neo/eGFP-PuroCL028HumanColorectal Carcinoma
HCT116-hNIS-Neo/Fluc-PuroCL009HumanColorectal Carcinoma
HCT116-hNIS-Neo/iRFP-PuroCL095HumanColorectal Carcinoma
A375-eGFP-PuroCL056HumanMelanoma
A375-Fluc-PuroCL055HumanMelanoma
A375-hNIS-PuroCL058HumanMelanoma
A375-iRFP-NeoCL088HumanMelanoma
A375-Fluc-Neo/eGFP-PuroCL085HumanMelanoma
A375-Fluc-Neo/hNIS-PuroCL087HumanMelanoma
A375-hNIS-Neo/eGFP-PuroCL086HumanMelanoma
A375-iRFP-Neo/Fluc-PuroCL089HumanMelanoma
A375-iRFP-Neo/hNIS-PuroCL090HumanMelanoma
PC3-Fluc-Neo/iRFP-PuroCL124HumanProstate
PC3-Fluc-PuroCL122HumanProstate
PC3-eGFP-NeoCL123HumanProstate
PC3-eGFP-Neo/Fluc-PuroCL125HumanProstate
A20-eGFP-Neo/Fluc-PuroCL152Mouse (Mus musculus)Lymphoma
A20-Fluc-PuroCL147MouseLymphoma
4T1-Fluc-Neo (monoclonal)CL126MouseMammary Carcinoma
4T1-mNIS-Puro/Fluc-NeoCL066MouseMammary Carcinoma
4T1-Fluc-Neo/eGFP-PuroCL023MouseMammary Carcinoma
4T1-Fluc-Neo/iRFP-PuroCL078MouseMammary Carcinoma
4T1-mNIS-Neo/eGFP-PuroCL025MouseMammary Carcinoma
4T1-mNIS-Neo/iRFP-PuroCL108MouseMammary Carcinoma
4T1-mNIS(monoclonal)CL117MouseMammary Carcinoma
4T1-mNIS-PuroCL065MouseMammary Carcinoma
4T1-iRFP-PuroCL094MouseMammary Carcinoma
4T1-eGFP-PuroCL021MouseMammary Carcinoma
B16F10-Fluc-hNISCL139MouseMelanoma
B16F10-mNIS-PuroCL057MouseMelanoma
B16F10-Fluc-Neo/iRFP-PuroCL110MouseMelanoma
B16F10-eGFP-PuroCL053MouseMelanoma
B16F10-Fluc-PuroCL052MouseMelanoma
B16F10-Fluc-Neo/eGFP-PuroCL068MouseMelanoma
B16F10-mNIS-Neo/eGFP-PuroCL067MouseMelanoma
B16F10-mNIS-Neo/iRFP-PuroCL109MouseMelanoma
B16F10-mNIS (monoclonal)CL118MouseMelanoma
B16F10-Fluc-Neo/mNIS-PuroCL069MouseMelanoma
B16F10-iRFP-PuroCL099MouseMelanoma
CT26.WT-eGFP-PuroCL044MouseColorectal Carcinoma
CT26.WT-Fluc-NeoCL043MouseColorectal Carcinoma
CT26.WT-Fluc-Neo/eGFP-PuroCL046MouseColorectal Carcinoma
CT26.WT-Fluc-Neo/iRFP-PuroCL092MouseColorectal Carcinoma
CT26.WT-iRFP-NeoCL091MouseColorectal Carcinoma
CT26.WT-iRFP-Neo/mNIS-PuroCL093MouseColorectal Carcinoma
CT26.WT-mNIS (monoclonal)CL119MouseColorectal Carcinoma
CT26.WT-mNIS-Neo/eGFP-PuroCL045MouseColorectal Carcinoma
CT26.WT-mNIS-PuroCL061MouseColorectal Carcinoma
LL/2-eGFP-PuroCL051MouseLewis Lung Carcinoma
LL/2-Fluc-Neo/eGFP-PuroCL073MouseLewis Lung Carcinoma
LL/2-Fluc-PuroCL050MouseLewis Lung Carcinoma
LL/2-iRFP-PuroCL111MouseLewis Lung Carcinoma
LL/2-mNIS (monoclonal)CL114MouseLewis Lung Carcinoma
LL/2-mNIS-Neo/eGFP-PuroCL071MouseLewis Lung Carcinoma
LL/2-mNIS-Neo/Fluc-PuroCL072MouseLewis Lung Carcinoma
LL/2-mNIS-PuroCL054MouseLewis Lung Carcinoma
EMT6-eGFP-PuroCL153MouseMammary carcinoma
EMT6-eGFP-Neo/Fluc-PuroCL155MouseMammary carcinoma
EMT6-Fluc-PuroCL154MouseMammary carcinoma
Hepa1-6 (Hepatoma)CL128MouseC57/L hepatoma
Hepa1-6-Fluc-NeoCL130MouseC57/L hepatoma
Hepa1-6-Fluc-Neo/eGFP-PuroCL133MouseC57/L hepatoma
Hepa1-6-iRFP-PuroCL131MouseC57/L hepatoma


Release time:2026-03-24